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Abstract—In case-control studies in which case and control enrollment periods are not 
identical, exposure status for time-dependent variables is often measured relative to a 
reference date. Using data from a case-control study of the relation between cervical 
cancer and oral contraceptive (OC) use in which control enrollment began 6 months 
after the end of case enrollment, we evaluated the effect on odds ratios from using five 
different reference dates to determine the controls' exposure status. The choice of 
reference date had little effect on the odds ratios in this study. Reference dates for 
time-dependent exposure variables should be considered carefully in studies when case 
and control enrollment periods are not identical. 
Case-control study 	 Odds ratios 	 Relative risk 
INTRODUCTION 
Case—control studies of rare diseases often re-
quire long or retrospective case enrollment 
periods to ensure adequate numbers of partici-
pants. In some instances, case and control en-
rollment periods are not identical. To ensure 
that cases and controls in studies with non-iden-
tical enrollment periods have a similar lifetime 
opportunity for exposure to time-dependent fac-
tors, many investigators assign subjects a refer-
ence date and consider only those exposures 
that occurred before this date. 
In our recent study of the relation between 
oral contraceptives (OCs) and cervical cancer in 
Costa Rica, case-patients identified through a 
tumor registry were eligible if diagnosed from 
January 1982 through March 1984 [1]. Only OC 
use before the date of the case-patient's diagnos-
tic biopsy was considered as a possible etiologic 
exposure. The controls were identified through  
a nationwide household survey from September 
1984 through February 1985. A single reference 
date, 15 February 1983, the midpoint of the case 
diagnosis period, was assigned to all controls. 
Only OC use before this reference date was 
considered for each control. Exposure data was 
subsequently calculated prior to the reference 
date for each control subject. This paper sum-
marizes our investigation into the effects of this 
reference date choice for the controls on the 
resulting odds ratios and confidence intervals 
for the relation between OC use and invasive 
cervical cancer and carcinoma in situ of the 
cervix. 
METHODS 
Detailed methods of this population-based 
case—control study have been previously re-
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cases of carcinoma in situ [CIS) and 293 cases 
of invasive cervical cancer) enrolled in this 
study were selected from the Costa Rican Na-
tional Tumor Registry. These cases were 
women who were newly diagnosed from 1 Jan-
uary 1982 through 31 March 1984. This period 
was defined as the case enrollment period. Be-
cause cases were interviewed up to several 
years after their diagnosis, their OC use was 
calculated relative to their date of diagnosis, 
not their date of interview. For example, if a 
woman first used oral contraceptives after her 
date of diagnosis, she was classified as having 
never used oral contraceptives. Interviewers at-
tempted to enhance recall by recording import-
ant life events and intervals of contraceptive 
use on a month-by-month life history calendar 
[3]. 
The 938 controls enrolled in this study were 
chosen using a one-time, nationwide household 
survey conducted from September 1984 
through February 1985. Cluster sampling was 
based on the June 1984 national census 
sampling frame with an interview completion 
rate of 92.8%. They were interviewed in person 
using the same standardized questionnaire as 
was used for case interviews. Since, by defi-
nition, the controls were disease-free, they did 
not have a date of disease diagnosis and hence 
did not have an obvious reference date. In the 
primary analysis [I], all controls were assigned 
the midpoint of the case enrollment period as 
their reference date to ensure that their lifetime 
opportunity for OC use was similar to that of 
the cases. 
To assess the effect that our choice of a 
reference date for the controls had on the 
resulting odds ratios, we evaluated four ad-
ditional choices of reference dates for the con-
trol subjects: a different, randomly chosen date 
from 1 January 1982 through 31 March 1984 
(the range of diagnosis dates for the cases) for 
each control; the date of each control's inter-
view; the endpoint of the case enrollment 
period (a single date for all controls); and the 
beginning of the case enrollment period (a 
single date for all controls). The randomly 
chosen date was generated using Fishman and 
Moore's method adapted by SAS [4]. 
We then calculated odds ratios (OR) and 
95% confidence intervals (CI) using each of the 
four additional reference dates and compared 
them with the OR and 95% CI calculated using 
the original reference date, the midpoint of the 
case enrollment period. For each analysis, we  
calculated odds ratios using the logistic re-
gression model [4]. The model included as inde-
pendent variables ever use of OCs and age at 
the reference date plus the following confound-
ing factors, all of which were determined rela-
tive to the assigned reference date: gravidity; 
number of lifetime sex partners; age at first 
coitus; history of any sexually transmitted dis-
ease or pelvic inflammatory disease; and his-
tory of Pap smears before 1982 (the beginning 
of the case enrollment period). The total num-
ber of eligible controls in the final models 
varied slightly for each analysis for two 
reasons: first, age at reference date varied 
according to which reference date was used 
and only women age 25-58 years at their refer-
ence date were included in analyses, and sec-
ond, the confounding factor age at first coitus 
was included in the final model and only 
women who had intercourse at least once be-
fore their reference date were included in 
analyses. The analyses included only those 
women for whom values for all confounding 
factors were known. In all analyses, women 
who had never used OCs served as the refer-
ence group. 
RESULTS 
Very little difference existed in the odds 
ratios reported for any of the five reference 
date choices for either invasive cancer or CIS 
(Table 1). The slight differences in odds ratios 
were dependent upon the proportion of cases 
whose date of diagnosis was before or after the 
chosen reference date for the controls. As the 
control reference date was moved later in time, 
the number of controls classified as having 
used OCs before their reference date increased 
slightly. Thus, the odds ratios decreased when 
controls were assigned later reference dates. 
In this study, the cases' dates of diagnosis 
were fairly uniformly distributed over the en-
rollment period such that 48.0% of the cases 
were enrolled before the midpoint of the 
case enrollment period. This may explain 
why use of different reference dates did not 
appreciably change the odds ratios. The in-
terpretation of the results was unchanged: 
compared with women who had never used 
OCs, women who had used OCs had no 
increase in risk of invasive cervical cancer 
and only a slightly elevated risk of CIS, regard-
less of which control reference date was 
used[1]. 
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table 1. Risk of invasive cervical cancer and carcinoma in situ associated with use of oral contraceptives by reference date 




Number of cases Number of controls* 
Odds 
ratio 
(OR) 95% CI 
Ever 	 Never 
used OCs used OCs 
Unknown if 	 Ever 	 Never 
used OCs 	 used OCs used OCs 
Unknown if 
used OCs 
Invasive Cervical Cancer 
Randomt 48 81 10 292 332 56 0.83 0.51-1.33 
Beginning of case 
enrollment (1/1/82) 48 81 10 273 324 53 0.84 0.52-1.37 
Midpoint of case 
enrollment (2/15/83) 48 81 10 300 331 56 0.79 0.49-1.28 
End of case 
enrollment (3/31/84) 48 81 10 317 327 56 0.71 0.44-1.14 
Date of interview 48 81 10 324 324 59 0.64 0.40-1.03 
Carcinoma in situ 
Randomt 256 111 25 292 332 56 1.63 1.19-2.25 
Beginning of case 
enrollment (1/1/82) 256 1 1 1 25 273 324 53 1.67 1.21-2.31 
Midpoint of case 
enrollment (2/15/83) 256 1 1 1 25 300 331 56 1.59 1.15-2.18 
End of case 
enrollment (3/31/84) 256 111 25 317 327 56 1.43 1.04-1.96 
Date of interview 256 111 25 324 324 59 1.29 0.94-1.77 
*Total number of controls varies in each analysis because of exclusion of controls with unknown or invalid values for age 
and confounding factors. 
tRandomly assigned date between 1 January 1982 and 31 March 1984. 
DISCUSSION 
In summary, the use of different reference 
dates for the controls had little effect on the final 
risk estimates obtained in this study. However, 
varying the reference date for the controls could 
alter conclusions based on statistical signifi-
cance drawn from a study as evidenced by the 
fact that for CIS, only one of the five reference 
date choices yields a 95% CI which includes 1. 
Since the cases' dates of diagnosis were fairly 
uniformly distributed over the 27-month enroll-
ment period, assigning each control a different 
reference date randomly selected from the be-
ginning to the end of the enrollment period 
would provide the controls with a lifetime OC 
exposure opportunity most similar to that of 
the cases. However, the results obtained 
were not markedly different from those 
from any of the other methods. Further, there 
are practical disadvantages to random assign-
ment of control reference dates. For a given 
set of 938 reference dates chosen randomly 
from the case enrollment period, there are 
938! = 938 x 937 x 936 x 	 x 3 x 2 x 1 ways 
to assign each of these reference dates to each 
control. Theoretically, the way in which these 
dates are assigned may cause the calculated 
exposure values to change enough to cause the 
odds ratios to vary, depending on which control 
is assigned which reference date. Investigating 
all possible control reference date assignments is  
necessary to assess the effect of date reassign-
ment on the final estimates, an impractical 
procedure for a data set this large. Other disad-
vantages are that this method, when used with 
logistic regression, is very computer-intensive 
and the methods are difficult to describe. 
In this study, using each control's interview 
date as her reference date also has drawbacks. 
The cases were diagnosed between 1 January 
1982 and 31 March 1984 and their exposures 
were truncated at the date of diagnosis; how-
ever, the controls were interviewed between 13 
September 1984 and 28 January 1985. Because 
all of the controls were interviewed several 
months after the end of the case enrollment 
period, using their interview date as the refer-
ence date allows the controls, as a group, to 
have been at risk of OC exposure for a longer 
period of time than the cases, assuming OC 
availability was constant over time. Increasing 
the opportunity for exposure in the control 
group decreased the odds ratio for both the in 
situ and invasive analyses. 
The other three choices assigned a single 
reference date to all controls, either the begin-
ning (1 January 1982), the midpoint (15 Febru-
ary 1983), or the end (31 March 1984) of the 
case enrollment period. Using the beginning 
date gives an estimate that is greater than the 
odds ratio based on the midpoint of case enroll-
ment because it reduces the proportion of ex- 
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posed controls. Similarly, use of the end date 
gives an estimate that is less than the odds ratio 
based on the midpoint of case enrollment be-
cause it increases the proportion of exposed 
controls. Matching cases and controls on the 
month and year of birth and then using the 
corresponding case's diagnosis date as the con-
trol's reference date is the best way to ensure 
that the controls have a lifetime opportunity for 
OC exposure equal to that of the cases. How-
ever, even with a large number of controls, it is 
nearly impossible to obtain such a match post 
hoc. Given the limitations of these other 
methods, using the midpoint of the case enroll-
ment period seems to be the best choice, on 
practical grounds. Furthermore, in this study, 
results obtained using the midpoint of the case 
enrollment period easily approximate the results 
obtained using the randomly chosen date. In-
deed, the differences among the odds ratios for 
the five possible references date choices are 
minimal. 
Finally, it is likely that the effect of changing 
the reference date for controls is dependent 
upon the magnitude of the relative risk. The 
effect may also be related to sample size, the 
length of the enrollment period, and the uni-
formity of the distribution of case diagnosis 
dates over the enrollment period. Even though 
changing the reference date of the controls had 
little effect on the odds ratios for this data set, 
this effect may not be small for other studies. 
In conclusion, in case—control studies where 
case and control enrollment periods are not 
identical, the choice of a control reference date 
should be carefully considered. An investigation 
into how sensitive the results are to the choice  
of the reference date is warranted. If varying the 
reference date for the controls substantially 
affects the conclusions of the study, then an 
appropriate justification for the particular refer-
ence date chosen and a description of how 
alternative choices affect the conclusions should 
be provided. 
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